Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

PI plasmids 147

Keyword Abstract

Keyword

Abstract

urea: An alternative to a containing triple regimen in ART-naive H
e to protease inhibitor ( ) therapy in clinical practice: Usefulness
ts/Protease inhibitors ( ) are associated with viral load suppressi
therapy (including one )/Factors associated in a Hispanic cohor
ed/Protease inhibitors ( ) in the HIV+ homeless and marginally ho
TG)/Protease inhibitor ( ) use in women and children treated at sit
sure protease inhibitor ( ) and reverse transcriptase inhibitor (RTI
with protease inhibitor ( ) containing regimens: Is it equal for all?/
ing protease inhibitors ( ): economical impact on opportunistic inf
ed to protease inhibitor ( ) adherence among sexually active mennts/Protease inhibitor ( ) change within a triple antiretroviral ther
e of protease inhibitors ( ) in HIV infected patients over the age of
with protease inhibitor ( ) use in a large clinical practice/Two year
two protease inhibitor ( ) regimens (d4T+3TC+IDV vs. d4T+RTV
with protease inhibitor ( ) in HIV infected patients/Predictors of vi
ith protease inhibitors ( )/Comparison of viral load mean in the s
aved by parental AIDS/ Picking up the pieces: Caregivers of adole
nflammatory disease ( PID) in HIV+ and HIV- women/Clinical co
mongst PLWH/A on the Pilly Lutaaya Initiative - PLWH/A project/I
ion for nurses in China/ Pilot program in experiential HIV/AIDS ed
a (AIDS-NHL) patients: study/Idarubicin contained regimen i
pediatric clinic rotation/ study on attitudes and knowledge ab
STD/AIDS prevention: project/Education of road haullers an
LWAs in their family/ project in Thailand to improve the soc
ndian industry (CII): a pilot study/AIDS at the workplace in India
dication adherence - A study/Impact of THE (Tools for Healt
e programs: Results of testing in Poland, 1997/A simple met
haw drivers in Delhi - A study/Risk assessment for STD and
HIV prevalence area: A study/An HIV and sexual health need
of HIV in a rural area/A study of the epidemiology of HIV in a r
ombination therapies: A study/Psychological factors and adh
K coalition back to work project/UK coalition back to work
saquinavir (ANRS 069 study)/Resistance related mutations i
ence in HIV+ women: A investigation/Determinants of medic
protective device - A study/Acceptability of female condo
hina/Evaluation of a STD/HIV prevention program with girl
IV positive persons - A study/"Kootikuppala compound": A p
n Indian HIV patients: A study/Effect of unique herbal formula
f a triple combination study and traditional drugs in HIV-1 in
tively fit: A prospective, project in community-based HIV reha
d assistance AIDS/STD center for young people/Sanitary stra
h part of Switzerland: A study/Behavioural risk factors for hep
nce, China/Results of a intervention among girl-attendants at
I counselling centre - A project/Voluntary HIV testing and mo
ptococcal meningitis/A study of the treatment of elevated intr
ourly dosing regimen: A study/Indinavir 12 hour dosing an alt
s/Preliminary data of a study comparing two protease inhibit
As: Popular education, PINOY PLUS, and its power over its future/
her protease inhibitors ( PIs )/In vitro antiviral activity and pharmaco
iral protease inhibitors ( ) on serum lipids and glucose in HIV-inf
or protease inhibitors ( ): A clinical cohort study/HIV genotypic
nd pharmacokinetic ( PK ) profiles of KNI 272 when combined wit
HGC) bioavailability: A study in healthy volunteers (HV)/Riton
MP)/Pharmacokinetic ( ) interaction between nevirapine (NVP)
x (MAC) bacteremia/A placebo-controlled trial of rifabutin added
domized, double-blind, trial of erythromycin v
ults of an international, trial (ALRT 1057-503)
phase II, double-blind,, dose ranging study t
6-004]/A double-blind, study to assess the s
hase III, double-blind,, multicenter study to d
Thailand/Randomized trial of short-course or
e herbs: A randomized, trial/Treatment of HIV
he HIV positive patient: Placebo controlled trial of methylphenidat
ndard of care in Africa/ control trials of short-course antir
drens' participation in a placebo controlled trial- The PENTA I trial
I ulcers: A double-blind controlled clinical trial/Thalidomi
eers into a randomized, controlled phase I HIV-1 vaccine t
d patients/Double blind controlled trial of oral dehydroepi
1 transmission in utero/ Placenta infection in HIV-1 transmission in
not infected in full-term placenta of HIV-seropositive mothers und
a/Association between placental malaria infection and increased r
ected homosexual men/ Plasma zinc, copper, and mortality in HIV
32315
32337
32390
32403
389*/32406
32444
42277
42305
44247
60192
60321
60388
60547
60791
60805
60992
47*/44215
32128
34278
13477
22294
32447
33557
44211
13439
14271
410*/23178
23436
23522
23559
24282
543*/24288
32302
32342
33127
33340
42329
42385
42395
504*/42400
43213
43411
44316
60139
60231
60484
60791
34171
12339
12381
229*/32287
12339
42257
60623
22176
22189
618*/22277
22334
22340
22343
30*"/33163
42381
22429
35*"/42201
12261
32247
33219
42326
23277
23286
461 */23268
12118
21115
22393
32190

41164
164*/42141
42175
42180

over a 48-week period/ concentrations of saquinavir (SQV 511*/42261
yelitis in an HIV patient/ cell granuloma presenting as trans 60176
HIV-1 infected patients/ levels of pro-inflammatory cytokin 60488
fore after TB treatment/ viral load in HIV-1 and HIV-2 co-inf 60742
DS-associated wasting/ leptin levels in AIDS-associated w 60898
on of HIV-1 viral load in plasma: Influence of the HIV-1 subtype/Bli 11175
ysis of vitamin A and E levels in HIV+ ex-homeless subjec 12121
Detection of HIV RNA in below quantifiable limits associate 12128
ween delavirdine (DLV) levels, HIV RNA responses and D 12206
TC)/lnterim analysis of viral burden reductions and CD4 in 129*/12219
ad in blood and seminal of patients receiving antiretroviral t 12284
nough? Suppression of viral load below 20 copies/mL is ne 12364
ts in relation to indinavir levels in HIV-infected patients/Uro 12372
6te d'lvoire/HIV-1 RNA viral load and CD4 counts before a 13271
gression after knowing HIV-1 RNA level?/Is cell-associat 13308
an, Cote d'lvoire/HIV-1 viral load in tuberculosis patients w 13328
an, C6te d'lvoire/HIV-1 viral load and CD4 counts in surviv 13329
ubtypes, virus isolation, viral load, and clinical spectrum (th 21154
py induced reduction in virus load leads to decrease in lym 21163
I to CD4 cell count and HIV RNA copy number/Fas media 21165
al outcome/Increased levels of soluble adhesion molecul 21173
nd soluble factors in the /Correlation between HIV RNA an 21178
ation with Candida and HIV RNA in asymptomatic patients 22214
etween the detection of cytomegalovirus (CMV) DNA and 22265
of HIV-1 RNA copies in and CD4 counts to human papillo 22317
ison between seminal RNA (SP-RNA) and blood plasma 22339
ugs enough? Baseline viral load as a predictor of virologic 22359
dictors of undetectable viral loads in 250 HIV(+) women in 22365
olecular parameters in and PBMCs in naive patients with 22383
T despite undetectable virus/HIV replication persists in pa 22388
ur-drug combination in and lymph node cells: The Quadri- 22397
/Neutralizing antibody, and cervical viral burden in relation 23290
men with undetectable viral loads/Perceptions, attitudes, 23389
oad in seminal fluid and compartments/The impact of riton 23397
gh correlation between and seminal HIV-1 viral load in anti 23399
al load in breakfast and in HIV infected mothers/Determin 23400
ound HIV antibody and viral load in HIV infected patients r 31102
on rate of HGV in blood, but not seminal fluid plasma of HI 32101
ers correlate with HIV-1 viral load and are improved by hig 32139
sociated with increased HIV RNA/Increased resting energ 32168
ebrospinal fluid (CSF), and CNS involvement in HIV patie 32201
II sub-populations and of HIV+ individuals and HIV- cont 32210
te HIV pol sequence in and genital tract of women: Genital 334*/32279
genotypic mutations in HIV of patients failing tritherapy co 32301
itoring compliance and levels in patients treated with indin 512*/32330
pregnancy/Changes in viral load related to short-course or 33164
V-1 RNA levels in dried and whole blood spots/Multicente 33166
HIV-RNA quantitation in /Comparative evaluation of a new t 41132
NA quantitation from, peripheral blood mononuclear cel 41133
ion of HIV-2 viral load in /A competitive RT-PCR method fo 41136
cutainer~ Brand PPT"T preparation tubes for HIV viral load 41138
HIV-1 proviral DNA and RNA changes in advanced patient 41140
ymphocyte-derived and HIV-RNA viral loads in patients wit 41144
proved quantification of RNA for non-B HIV-1 subtypes usi 41154
P) by direct analysis of reverse transcriptase activity/Rap 41209
1 genomes detected in and blood mononuclear cells/Co 41217
soluble CD30 (sCD30) levels and the percentage of apopt 41235
ay (bDNA, RT-PCR) on HIV RNA decay/Effect of processi 42144
al HIV-1 RNA levels and viral load/Cervicovaginal HIV-1 R 42148
cy HIV study/Impact of HIV RNA on CD4 change and outc 42153
pinal fluid (CSF) versus HIV RNA levels in patients with Al 42170
ship with RNA levels in /HIV-1 cellular infectious load in pe 42176
V-1 viral load (bDNA) in samples in pediatric cases/Analyz 42178
decline of HIV-1 RNA in correlates with nelfinavir concentr 510*"/42259
ning triple therapy/Low levels of indinavir (IDV) are highly 42275
oncentrations in human /Methods to measure protease inh 42277
nal failure/Single-dose profiles of abacavir (1592, ABC) in 42278
odeling the dynamics in viral load and CD4+ lymphocyte c 43473
ess evaluation/Should PCR be used to target CMV proph 44242
ence of toxic factors on viral load in patients with HIV-1 dis 60264
f NASBA for monitoring HIV-1 RNA levels/The use of NAS 60306
A anti-HIV antibodies in and saliva from patients with HIV i 60587
s) for quantifying HIV-1 viral load/Usefulness of the new N 60679
ht shipment/Stability of HIV viral load in Vacutainer~ plas 60731

fy HIV-1-RNA in clinical samples/Ultra-sensitive HIV-1 Mo 60886
ng-term suppression of viremia despite antiviral discontinu 61000
s/Correlation between plasmatic levels of indinavir and inmunolo 12286
assurance program for viral load of HIV-1 by NASBA te 43463
taneous apoptosis and viremia in HIV infected patients 60975

pediatric HIV infection/
1 infected individuals/
function after one year/
rapy of HIV-1 infection/
s in early HIV infection/
her commercial assays/
n HIV-infected patients/
rognostic indicators/

L-selectin level correlates with viru
viral load reduction in an open-lab
viral load predicts cognitive functio
concentrations of IL-16, but not of
and genital tract viral load and ST
HIV-1 RNA quantification: Compa
viral load, CD4 count and p24 anti
immune activation marker levels c

42181 env and gag-containing plasmids for DNA immunization against H

21211